Varenicline, a pharmacotherapy for tobacco addiction, reduces alcohol consumption in humans and rodents. The therapeutic potential of varenicline would escalate if it also diminished conditioned responses elicited by alcohol-predictive cues, which can precipitate relapse in abstinent individuals. We investigated this application, along with the underlying neural substrates, using a robust preclinical assay in which relapse to alcohol-seeking was triggered by re-exposure to an alcohol-associated environmental context. Male, Long-Evans rats received Pavlovian conditioning sessions in which one auditory conditioned stimulus (CS+) was paired with 15% ethanol and a second conditioned stimulus (CS − ) was not. Ethanol was delivered into a port for oral consumption and port entries triggered by each CS were recorded. Extinction was then conducted in a different context where the CS+ and CS − were presented without ethanol. To stimulate relapse, both cues were subsequently presented without ethanol in the prior conditioning context. Systemic varenicline (0, 0.5 or 2.5 mg/kg; intraperitoneal) blocked context-induced relapse to alcohol-seeking without affecting the ability to make a port entry. It also reduced context-induced relapse to sucrose-seeking, but only at the 2.5 mg/kg dose. Neuropharmacological studies showed that context-induced relapse to alcohol-seeking was attenuated by bilateral microinfusion of varenicline (0.3 μl/side) into the nucleus accumbens (NAc; 0 or 3.5 μg), but not the ventral tegmental area (0, 2 or 4 μg). These data show for the first time that varenicline reduces relapse triggered by contexts that predict alcohol, and suggest that nicotinic acetylcholine receptors in the NAc are critical for this effect.
INTRODUCTION
A burgeoning literature indicates that varenicline, a pharmacotherapy for smoking cessation, may hold promise as a new treatment for alcohol use disorder. Varenicline reduces alcohol use in heavy-drinking smokers (Fucito et al, 2011; McKee et al, 2009; Mitchell et al, 2012) and alcoholdependent individuals (de Bejczy et al, 2015; Litten et al, 2013) . In rats, varenicline attenuates alcohol intake and operant alcohol-self administration, with either no effect on water intake and sucrose self-administration (Steensland et al, 2007) or an increase in the latter behavior (Wouda et al, 2011) . These and related data (Le Foll et al, 2011; O'Connor et al, 2009) suggest that varenicline selectively dampens behaviors maintained by pharmacological, as opposed to non-drug reinforcers (Guillem and Peoples, 2010) .
The therapeutic potential of varenicline would escalate if it also diminished reactivity to alcohol-predictive cues in abstinent individuals; however, this novel application has received limited empirical attention. In humans, varenicline reduced alcohol craving and cue-elicited activation of the orbitofrontal cortex, with no effect on drinking behavior (Schacht et al, 2014) . Varenicline dose-dependently attenuated cue-induced reinstatement of alcohol-seeking in rats (Funk et al, 2016; Wouda et al, 2011) , congruent with doserelated reductions in cue-induced cocaine- (Guillem and Peoples, 2010) and nicotine-seeking (Le Foll et al, 2011 , but see Wouda et al, 2011, and O'Connor et al, 2009) . Moreover, varenicline reduced transient increases in oral alcohol intake produced by repeated bouts of abstinence from alcohol in mice (Sajja and Rahman, 2013) . Thus, varenicline may diminish the relapse-inducing effects of alcohol-predictive cues on behavior.
In standard cue-induced reinstatement assays, operant responding is reinforced by drug delivery and a concurrent non-pharmacological stimulus. Following extinction where both the drug and nonpharmacological stimulus are withheld, reinstatement is triggered by response-contingent presentation of the nonpharmacological stimulus alone. Studies using this assay seldom ascertain that the nonpharmacological stimulus is devoid of intrinsic reinforcing properties that could either contribute to, or drive reinstatement (Caggiula et al, 2002) . In addition, this assay does not enable the investigation of drug-seeking responses that are elicited in response to cues that have come to predict drug availability through Pavlovian learning processes, which can provoke drug-seeking and drug-taking behaviors that lead to relapse (Litt et al, 2000) . Finally, a developing literature indicates that environmental contexts in which drugs are used can serve as powerful triggers for relapse (Bossert et al, 2004; Burattini et al, 2006; Chaudhri et al, 2008a,b; Crombag and Shaham, 2002; Janak and Chaudhri, 2010; Marinelli et al, 2007; Zironi et al, 2006) and the effects of varenicline on context-induced relapse are unknown. With these considerations in mind, the present studies tested the effects of varenicline on relapse using a robust, preclinical assay in which relapse was triggered by re-exposure to an alcohol-associated context. Dependent variables included entries into a fluid port where alcohol was delivered that were elicited by a conditioned stimulus that predicted alcohol, and port entries elicited by a different auditory stimulus that was never explicitly paired with alcohol. Control experiments examined the effect of varenicline on context-induced relapse to sucrose-seeking and on the expression of Pavlovian conditioned approach elicited by alcohol-and sucrose-predictive cues.
Varenicline binds to nicotinic acetylcholine receptors (nAChR), functioning as a potent, partial agonist at α4β2 nAChRs, a weak partial agonist at α3β2 and α6 nAChRs, a weak agonist at α3β4 nAChRs, and a potent full agonist at α7 nAChRs (Grady et al, 2010; Mihalak et al, 2006) . Interestingly, nAChRs may contribute to cue-driven alcohol-seeking. This hypothesis is suggested by a single study in which systemic infusion of mecamylamine, a non-selective nAChR antagonist, but not by dihydro-β-erythroidine (DHβE), an α4β2 nAChR antagonist, blocked the capacity of an alcoholpredictive, nonpharmacological stimulus to reinforce a novel operant response (Löf et al, 2007) . This behavior was also abolished by microinfusion into the ventral tegmental area (VTA) of either mecamylamine or α-conotoxin MII, a selective antagonist of α3β2 and α6 nAChRs (Löf et al, 2007) . Augmenting cholinergic tone within the VTA enhanced cueinduced relapse to heroin-seeking (Zhou et al, 2007) , which is consistent with antagonist studies. Together, these data suggest that acetylcholine acting at α3β2 and α6 nAChRs within the VTA may mediate conditioned behavioral responding elicited by alcohol-predictive cues.
Alcohol-associated cues increase extracellular dopamine in the nucleus accumbens (NAc; Katner and Weiss, 1999; Löf et al, 2007) and intra-VTA mecamylamine, but not DhβE, blocks this effect (Löf et al, 2007) . Thus, cholinergic signaling in the VTA may mediate conditioned firing of dopamine neurons in response to alcohol-predictive cues. However, increases in NAc dopamine can also be caused by activation of nAChRs located presynaptically on dopamine terminals in the NAc (Champtiaux et al, 2003; Grady et al, 2002) . There is little direct evidence that dopamine release through this mechanism, which is independent of the activity of VTA dopamine neurons, contributes to context-induced relapse of alcohol-seeking. However, this behavior does require functional activity in the NAc , as well as dopamine D1-like receptors in the NAc (Chaudhri et al, 2009) . Paradoxically, augmenting cholinergic tone in the NAc reduced cue-induced relapse to heroin-seeking (Zhou et al, 2007) , although it is unclear whether this manipulation influenced presynpatic dopamine release.
There are no studies to date that have examined the impact of intra-VTA or intra-NAc varenicline on relapse to alcoholseeking. However, varenicline in the NAc but not VTA reduced voluntary alcohol consumption in rats, highlighting a role for nAChRs in the NAc in alcohol reinforcement (Feduccia et al, 2014) . As the present studies found that systemic varenicline reduced context-induced relapse to alcohol-seeking, we examined the effect of intra-NAc or intra-VTA varenicline on this behavior to determine the neural loci of varenicline's effects.
MATERIALS AND METHODS

Subjects
Male, Long-Evans rats (Harlan, Indianapolis, IN, USA; 175-275 g on arrival) were single-housed in polycarbonate shoebox cages (44.5 cm × 25.8 cm × 21.7 cm) containing bedding (Sanichips, Harlan) on a 12 h light/dark cycle (lights on at 0700 h) with humidity around 44%. A nylabone (Nylabones, Bio-Serv) was provided in each cage. Rats had unrestricted access to food (Agribrands, Charles River) and water and were weighed and handled for 1 week before experiments commenced. All procedures were approved by the Concordia University Animal Research Ethics Committee and agree with recommendations from the Canadian Council on Animal Care.
Apparatus
Behavioral testing equipment is described in detail in the Supplementary Material.
Drugs and Solutions
Varenicline tartrate (Tocris, catalog number 3754) was dissolved in 0.9% sterile saline. Doses were based on the weight of the salt. A 15% ethanol solution (v/v) was prepared by diluting a 95% ethanol solution in tap water and a 10% sucrose solution (w/v) was prepared by dissolving sucrose in tap water.
Home-Cage Ethanol Exposure
Rats were acclimated to ethanol across 12 sessions of intermittent access to ethanol in the home-cage (Simms et al, 2008; Sparks et al, 2013; Wise, 1973) . Procedural details and data can be found in Supplementary Figure S1 .
Surgery
Standard stereotactic procedures were used to implant stainless steel guide cannulae (26 gauge, Plastics One, C315G) bilaterally into the VTA (AP − 5.80, ML ± 2.70 at a 14°angle from vertical, DV − 5.65) or NAc (AP +1.70, ML ± 2.85 at a 12°angle from vertical, DV − 4.20) using coordinates from bregma. Microinfusion injectors were 3 mm longer than the guide cannulae. Surgery occurred after seven sessions of Pavlovian discrimination training (PDT) had been conducted (see details below).
Intracranial Microinfusions
Microinfusions (0.3 μl in 1 min, 2 min diffusion) were conducted in the behavior testing room using 33 g injectors Varenicline reduces context-induced relapse F Lacroix et al (Plastics One, C315I) using standard procedures . Rats were habituated to sham microinfusions conducted during PDT and extinction.
Behavioral Procedures
Habituation. Rats were transported to the behavior testing room in their home cages and left there for 20 min. The next day they were weighed and handled in that same room. Twenty-four hours later, rats were weighed and then placed into a designated conditioning chamber for two 20 min sessions during which houselights were turned on, and port entries recorded. Chambers were set up as Context Type 1 and 2 consecutively, and the order of exposure to each context was counterbalanced such that half the rats were habituated to their PDT context first and half the rats were habituated to their extinction context first (see below). Context Type 1 consisted of black cardboard covering the Plexiglas walls and ceiling of the conditioning chamber, a Plexiglas insert over the chamber floor, and a lemon odour sprayed into the waste tray beneath the chamber floor. Context Type 2 consisted of clear, transparent walls and ceiling, a perforated metal floor insert, and an almond odour.
Pavlovian discrimination training. During PDT sessions (58 min, 5-6 days per week), rats learned to discriminate between one conditioned stimulus (CS+) that was paired with an unconditioned stimulus (US), and a second conditioned stimulus (CS − ) that was presented without the US. The US was either ethanol or sucrose, as specified below.
Each rat was weighed and placed into a designated conditioning chamber. The computer program was started and 5 min later houselights were illuminated. The CS+ and CS − were each presented 16 times, according to separate variable-time 67 s schedules. Conditioned stimuli (10 s) consisted of a clicker (2 Hz, 75-80 dB) or a continuous white noise (25 kHz, 80-85 dB). The US was delivered into the fluid port for oral consumption 4 s after the CS+ onset (0.2 ml/CS+ delivered over 6 s, 3.2 ml/session). Fluid ports were checked after each session, to ensure that the US had been consumed.
Half the conditioning chambers were set up as Context Type 1 and the remainder as Context Type 2. The context used for PDT was referred to as Context A. Designation of the white noise or clicker as the CS+ was counterbalanced across Context Type.
Extinction. Following PDT, extinction sessions were conducted in the Context Type that had not been experienced during PDT (Context B). The CS+ and CS − were presented as before but the US was not delivered (syringe pumps empty and turned off).
Relapse test. Twenty-four hours after the last extinction session, the capacity of the PDT context to trigger relapse was assessed. The test was identical to a PDT session in Context A in how the CS+ and CS − were presented. However, syringe pumps were turned off and US delivery was withheld.
Experiment 1a: Effect of Systemic Varenicline on Relapse to Alcohol-and Sucrose-Seeking
This study compared the effect of varenicline on contextinduced relapse to alcohol-and sucrose-seeking.
For Group 1 (n = 10) the US consisted of ethanol. These rats received exposure to ethanol in the home cage, as described in Supplementary Figure S1 . For Group 2 (n = 14) the US consisted of sucrose. Half the rats in this group were exposed to ethanol in the home cage, while the remainder were exposed to water in place of ethanol. This manipulation allowed us to examine the impact of home-cage ethanol exposure on subsequent conditioning. We found no differences between ethanol and water-exposed rats in the acquisition or extinction of PDT (Supplementary Figure S2) .
A within-subjects design was used to examine the impact of varenicline (0, 0.5 or 2.5 mg/kg; 1 ml/kg; intraperitoneal; counterbalanced across tests) on context-induced relapse to alcohol-seeking (doses based on Wouda et al, 2011) . Test 1 occurred after 19 PDT and 8 extinction sessions. Subsequent tests were separated by 4 PDT retraining sessions and 4 extinction sessions. Injections were administered in the colony room 20-30 min before the test. Rats were habituated to a saline injection before extinction session 6 and PDT retraining session 2.
Experiment 1b: Effect of Systemic Varenicline on PDT
To determine whether varenicline affected the ability to make a port entry, we administered varenicline before a PDT session in which the CS+ was paired with the US.
Following the third relapse test, rats from Experiment 1a received eight PDT retraining sessions in Context A. Varenicline (0 or 2.5 mg/kg; 1 ml/kg; intraperitoneal) was administered before PDT retraining sessions 4 and 8 using a counterbalanced, within-subjects design.
Data from two rats from Group 1 that failed to discriminate between the CS+ and CS − , and did not consume all the ethanol presented during PDT, were excluded from Experiment 1.
Experiment 2: Effect of Intra-VTA Varenicline on Relapse to Alcohol-Seeking
At 20-30 min before the relapse test in Context A, varenicline (0, 2 or 4 μg; 0.3 μl/hemisphere) was bilaterally microinfused into the VTA using a counterbalanced, within-subjects design (n = 18; doses based on Feduccia et al, 2014) . Test 1 occurred after 18 PDT sessions in Context A and 8 extinction sessions in Context B. Subsequent tests were separated by three PDT retraining and eight extinction sessions.
Experiment 3: Effect of Intra-NAc Varenicline on Relapse to Alcohol-Seeking
At 20-30 min before the relapse test in Context A, varenicline (0 or 3.5 μg; 0.3 μl/hemisphere) was bilaterally microinfused into the NAc using a counterbalanced, withinsubjects design (n = 12; doses based on Feduccia et al, 2014) . Published data show that varenicline (0.5, 1 or 2 μg; 0.5 μl/ hemisphere) in the NAc core-shell border, but not the NAc core or shell separately, reduced alcohol intake in the home cage (Feduccia et al, 2014) . We tested a higher varenicline dose because pilot data showed that 1 and 3 μg (0.3 μl/ hemisphere) doses in the NAc had only modest effects on port entry behavior.
The first relapse test occurred after 18 PDT sessions and 8 extinction sessions; however, response levels in test 1 were uncharacteristically low. Therefore, two subsequent tests were conducted that were identical to test 1, except that midway during the 5 min delay before the onset of the houselight a 0.2 ml drop of ethanol was delivered into the fluid port to optimize the relapse effect. Each test was separated by four PDT retraining and five extinction sessions and only data from tests 2 and 3 are reported.
We and others have shown previously that a 0.2 ml drop of alcohol can boost relapse in an instrumental alcohol-seeking task (Chaudhri et al, 2008b; Wouda et al, 2011) . This drop exposes rats to the sensory properties of alcohol (eg, taste and smell) and would not produce a pharmacological effect. To further assess the behavioral effects of this sensory prime, we examined the possibility that the 0.2 ml drop of ethanol may have reinstated behavior independently of context. Following one PDT retraining session in Context A and two extinction sessions in Context B, half of the rats received the CS+ and CS − without ethanol in Context A, whereas the other half received both cues without ethanol in Context B. Twenty-four hours later the test was repeated in the opposite context for each rat. A 0.2 ml drop of ethanol was delivered into the port at the start of each test. We found a significant relapse to alcohol-seeking in Context A but not in Context B, confirming that the drop of ethanol did not provoke relapse outside the alcohol context (Supplementary Figure S3) .
Histology
Standard light microscopy was used to examine injector tip placements in 50 μm coronal sections that were stained with cresyl violet . Five rats with VTA implants (Supplementary Figure S4) and four with NAc implants (Supplementary Figure S5) were excluded because of incorrect placements identified using the 1998 Paxinos and Watson rat brain atlas (Paxinos and Watson, 1998) , or tissue damage.
Statistical Analyses
The number of port entries during a 10 s interval immediately before each CS+ and CS − was subtracted from the number of port entries during each corresponding CS, resulting in a normalized measure of port entries that accounted for differences in baseline responding. The number of port entries made during each CS+ trial at test was recorded. The number of non-CS port entries was calculated by subtracting port entries during the CS+ and CS − from the total number of port entries.
Relapse was assessed by comparing test data to an extinction baseline derived by averaging responding across the two extinction sessions immediately before the corresponding test. Relapse in saline-infused rats was assessed using planned, paired samples t-tests The effect of varenicline was assessed using repeatedmeasures ANOVA across the within-subjects factors of Dose (as per experiment) and CS. Significant Dose × CS interactions were pursued by targeted ANOVA, to examine the impact of Dose on responding during each CS. Where appropriate, post-hoc comparisons were conducted using Tukey's HSD to correct for multiple comparisons.
The significance level for all analyses was p ⩽ 0.05. The Greenhouse-Geisser correction was used whenever Mauchly's Test for Sphericity was significant. Analyses were run using SPSS (version 20.0).
RESULTS
In each experiment, port entries elicited by the CS+ increased across PDT sessions in Context A, whereas port entries during the CS − stabilized at a lower level. During extinction in Context B, CS+ port entries decreased across sessions (Supplementary Figure S6) . In Experiment 1, overall levels of responding during PDT were significantly higher when the US was sucrose, compared with alcohol (Supplementary Figure S6) . Consequently, data from these two groups were analyzed separately. As there was no impact of prior alcohol exposure on conditioning in rats that received sucrose as the US (Supplementary Figure S2 ) data from these two groups were combined for subsequent analyses.
Experiment 1a: Effect of Systemic Varenicline on Relapse to Alcohol-and Sucrose-Seeking
In saline-injected rats, re-exposure to the PDT context (Context A) following extinction in a different context (Context B) triggered a relapse in alcohol-seeking elicited by the CS+ (Figure 1a) . Compared to extinction, there was a selective increase in port entries triggered by the CS+ (t(7) = − 3.61, p = 0.009), but not the CS − (t(7) = − 0.09, p40.05).
Systemic varenicline significantly attenuated contextinduced relapse to alcohol-seeking (Figure 1b : CS, F(1,7) = 36.25, p = 0.001; Dose, F(2,14) = 7.91, p = 0.019; CS × Dose, F(2,14) = 9.51, p = 0.002). Subsequent analyses on CS+ port entries revealed a significant effect of Dose (F(2,14) = 9.20, p = 0.003), with no impact of varenicline on CS − port entries (Dose, F(2,14) = 0.24, p40.05). Relative to saline, alcohol-seeking elicited by the CS+ was reduced by 0.5 (po0.05) and 2.5 mg/kg (po0.05) of varenicline, with no difference between the two varenicline doses (p40.05).
To further examine the impact of varenicline we determined the number of port entries elicited by consecutive blocks of two CS+ trials at test (Figure 1c) . Alcohol-seeking triggered by the CS+ decreased within test sessions, which occurred in the absence of alcohol delivery (Block, F(7,49) = 7.23, p = 0.004). Varenicline reduced CS+ port-entries (Dose, F(1,7) = 14.78, p = 0.023), without affecting the overall pattern of responding (Block × Dose, F(7,49) = 0.89, p40.05).
Saline-injected rats showed context-induced relapse to sucrose-seeking (Figure 1d ). Compared with extinction, there was a selective increase in port entries triggered by the CS+ (t(13) = − 5.23, po0.001), with no difference in CS − responding (t(13) = − 0.36, p40.05).
Systemic varenicline reduced context-induced relapse to sucrose-seeking (Figure 1e ), but only at the highest dose tested (CS, F(1,13) = 67.94, po0.001; Dose, F(2,26) = 4.92, p = 0.015; CS × Dose, F(2,26) = 5.75, p = 0.009). Subsequent analyses on CS+ responding found a significant main effect of Dose (F(2,26) = 5.63, p = 0.009), with no impact of Varenicline reduces context-induced relapse F Lacroix et al varenicline on CS − responding (F(2,26) = 1.36, p40.05). The 2.5 mg/kg dose of varenicline reduced CS+ port entries relative to saline (po0.01) and the 0.5 mg/kg dose (po0.05). Unlike with alcohol, 0.5 mg/kg of varenicline did not affect CS+ port entries relative to saline (p40.05). Sucrose-seeking elicited by consecutive blocks of 2 CS+ trials (Figure 1f ) decreased within test sessions (Block, F(7,91) = 16.91, po0.001). Varenicline reduced the overall level of sucrose-seeking elicited by the CS+ (Dose, F(2,26) = 4.00, p = 0.031), with a differential impact across CS+ trials for different doses (Block × Dose, F(14, 182) = 2.43, p = 0.004). To investigate this interaction, follow-up repeated-measures ANOVA were conducted to compare pairs of doses across blocks. There was a main effect of Block for each comparison (Saline vs 0.5 mg/kg, F(14,182) = 2.43, p = 0.004; Saline vs 2.5 mg/kg, F(7,91) = 14.82, po0.001; 0.5 vs 2.5 mg/kg, F(7,91) = 7.48, po0.001). There was a main effect of Dose when comparing saline and 2.5 mg/kg (F(1,13) = 9.41, p = 0.009), but not when comparing 0.5 mg/kg with saline (F(1,13) = 0.80, p40.05) or 2.5 mg/kg (F(1,13) = 3.44, p = 0.086). There was a Block × Dose interaction when comparing saline with 2.5 mg/kg (F(7,91) = 3.28, p = 0.027), but not when comparing 0.5 mg/ kg with saline (F(7,91) = 2.80, p = 0.057) or 2.5 mg/kg (F(7,91) = 1.11, p40.05). Follow-up paired samples t-tests found that port entries were significantly lower following 2.5 mg/kg of varenicline compared to saline in blocks 2 (t(13) = 3.49, p = 0.004) and 3 (t(13) = 3.52, p = 0.004).
Varenicline reduced port entries that occurred during non-CS intervals (Figure 2a and b) . Repeated-measures ANOVA found a significant main effect of Dose in both alcohol-(F(2,14) = 8.75, p = 0.014) and sucrose-trained (F(2,26) = 7.20, p = 0.003) rats. In alcohol-trained rats, compared with saline there was a significant reduction in non-CS responding following 2.5 mg/kg (po0.05). There was no difference in non-CS responding between saline and 0.5 mg/kg of varenicline (p40.05) or between both varenicline doses (p40.05). In sucrose-trained rats, compared with saline non-CS port entries were reduced following 2.5 mg/kg (po0.01), but not 0.5 mg/kg of varenicline (p40.05). Non-CS responding was also lower following 2.5 mg/kg, compared to 0.5 mg/kg of varenicline (po0.05). (Figure 3b) . In both cases, responding was higher during the CS + than the CS − (CS: alcohol, F(1,7) = 90.56, po0.001; sucrose, F (1,13) = 372.50, po0.001), with no main effects of Dose (alcohol, F(1,7) = 0.35, p40.05; sucrose, F(1,13) = 0.48, p40.05), and no CS × Dose interactions (alcohol, F(1,7) = 0.82, p40.05, sucrose: F(1,13) = 0.93, p40.05). Port entries elicited by consecutive blocks of two CS+ trials at test (Figure 2c and d) remained consistent within test sessions (Block: alcohol, F(7,49)= 2.12, p = 0.059; sucrose, F(7,91) = 0.69, p40.05), with no impact of varenicline on behavior (Dose: alcohol, F(1,7) = 1.08, p40.05; sucrose, F(1,13) = 0.60, p40.05; Block × Dose: alcohol, F (7,49) = 1.62, p40.05; sucrose, F(7,91) = 0.57, p40.05). with no difference across phase in CS − responding (t(12) = 0.00, p40.05). Intra-VTA varenicline did not impact relapse (Figure 4b ). At test, more port entries were elicited by the CS+ than the CS − (CS, F(1,12) = 47.98, po0.001), with no impact of varenicline on behavior (Dose, F(2,24) = 0.44, p40.05; CS × Dose, F(2,24) = 0.294, p40.05). There was no effect of Varenicline reduces context-induced relapse F Lacroix et al intra-VTA varenicline on the number of port entries across blocks of CS+ trials (Figure 4c ; Block, F(7,84) = 8.24, p = 0.004; Dose, F(2,24) = 0.34, p40.05; Block × Dose, F (14,168) = 1.28, p40.05), or on non-CS port entries (Figure 4d ; Dose, F(2,24) = 0.47, p40.05). The placement of injector tips within the VTA is shown in Figure 4e .
Experiment 3: Effect of Varenicline in the NAc on Relapse to Alcohol-Seeking
Rats receiving intra-NAc saline showed context-induced relapse to alcohol-seeking (Figure 5a ). Compared with extinction in Context B, they made significantly more CS+ port entries (t(7) = − 2.39, p = 0.048) at test in Context A, with no difference across phase in CS − port entries (t(7) = − 1.87, p40.05).
Intra-NAc varenicline significantly attenuated relapse (Figure 5b : CS, F(1,7) = 9.69, p = 0.017; Dose, F(1,7) = 11.62, p = 0.011; CS × Dose, F(1,7) = 9.40, p = 0.018). Paired samples t-tests confirmed that intra-NAc varenicline reduced port entries during the CS+ (t(7) = 3.40, p = 0.011), with no impact on CS − responding (t(7) = 1.78, p40.05). The effect of varenicline was most pronounced near the beginning of the test session (Figure 5c ). The number of port entries during blocks of CS+ trials decreased as a function of Block (F(7,49) = 6.90, p = 0.007) and was lower following varenicline than saline (Dose, F(1,7) = 11.46, p = 0.012). A significant Block × Dose interaction (F(7,49) = 3.95, p = 0.034) was found and follow-up paired samples t-tests indicated that varenicline significantly reduced the number of port entries in Blocks 1 (t(7) = 3.24, p = 0.014), 2 (t(7) = 2.54, p = 0.039) and 4 (t(7) = 3.42, p = 0.011), relative to saline. Intra-NAc varenicline also reduced Non-CS port entries, relative to saline (Figure 5d ; t(7) = 3.06, p = 0.018). The placement of injector tips within the NAc is shown in Figure 5e .
To determine the effect of intra-NAc varenicline on general locomotor activity we examined latency (in seconds) to the first port at test. In this analysis 2 rats in the varenicline group that made zero port entries were assigned a maximum latency of 3480.95 s, which represents the duration of the session. There was no significant difference in latency between saline (mean ± SEM = 63.80 ± 15.47) and varenicline (mean ± SEM = 1093.66 ± 548.84) tests (t(7) = − 1.85, p40.05).
DISCUSSION
Varenicline, a tobacco cessation product used in humans, reduced context-induced relapse to alcohol-seeking. At a high dose, systemically infused varenicline reduced relapse to alcohol-and sucrose-seeking, without affecting the capacity to make a port entry response. However, at a low dose, varenicline reduced relapse to alcohol-but not sucroseseeking. Although we anticipated that nAChRs in both the VTA and NAc would be implicated, only intra-NAc varenicline attenuated relapse to alcohol-seeking.
The finding that systemic administration of 2.5 mg/kg varenicline attenuated context-induced relapse to both alcohol-and sucrose-seeking appears to contradict evidence that similar varenicline doses (2.0 or 2.5 mg/kg) reduce alcohol self-administration, with no impact on sucrose selfadministration (Steensland et al, 2007) or an increase in the latter behavior (Wouda et al, 2011) . In our task, however, relapse was triggered by a return to the context in which alcohol or sucrose was previously consumed and neither alcohol nor sucrose was delivered at test. Thus, the present results suggest for the first time that cholinergic processes are part of a general mechanism that mediates context-induced relapse. This hypothesis is consistent with data showing that activation of nAChRs leads to increased drug-seeking in contexts associated with drug consumption (Cortright et al, 2012; Hall et al, 2010) , suggesting that these receptors are involved in the mechanisms by which drug contexts elicit drug-seeking. If cholinergic activity is implicated in the retrieval of contextual associations, then varenicline may disrupt context-induced relapse by perturbing the interaction of endogenous acetylcholine at nAChRs. Interestingly, 0.5 mg/kg of varenicline reduced contextinduced relapse to alcohol-but not sucrose-seeking. These results are consistent with findings that low doses of varenicline (0.1 and 0.3 mg/kg) attenuated cue-induced reinstatement of cocaine-seeking, with no impact on cueinduced reinstatement of sucrose-seeking (Guillem and Peoples, 2010) . The differential effect of low dose varenicline in the present research may be attributable to changes in nAChR expression levels, subunit composition, or affinity brought about by prolonged exposure to alcohol (Yoshida et al, 1982) .
Varenicline did not affect conditioned responding elicited by the CS+ when it was paired with the US, suggesting that the reduction in port entries during relapse tests was not caused by a depressant effect on locomotor activity. Instead, our data suggest that cholinergic processes may be particularly important for conditioned responding that is maintained by the memory of a learned association between a CS and US. The lack of effect of varenicline on port entries when the CS+ was paired with alcohol provides an interesting contrast to studies in which varenicline reduced voluntary alcohol intake or operant alcohol self-administration (Steensland et al, 2007; Wouda et al, 2011) . Unlike in the latter procedures, rats in the present studies did not control the timing of alcohol delivery or the volume of alcohol available per session, which could explain these differences. However, a broader range of varenicline doses should be tested to confirm a lack of effect of varenicline on the expression of Pavlovian conditioned alcohol-seeking.
Instrumental responding maintained by an alcoholassociated cue requires α3β2 and α6 nAChRs, but not α4β2 nAChRs in the VTA (Löf et al, 2007) . Given that varenicline is a weak partial agonist at α3β2 and α6 nAChRs and that enhancing cholinergic tone within the VTA augments cue-induced relapse to heroin-seeking (Zhou et al, 2007) , it was surprising that intra-VTA varenicline had no impact on context-induced relapse to alcohol-seeking. Because varenicline is also a potent partial agonist of α4β2 nAChRs, our results corroborate the suggestion that α4β2 nAChRs in the VTA are not involved in cue-driven alcohol-seeking (Löf et al, 2007) . Doses used in the present study (2 and 4 μg/0.3 μl/hemisphere) were higher than those employed in an earlier report in which intra-VTA varenicline (1 and 2 μg/0.5 μl/hemisphere) had no impact on oral alcohol intake (Feduccia et al, 2014) . Future studies should test lower varenicline doses before ruling out the VTA as a neural target for the action of varenicline, as low varenicline doses sometimes produce effects that are not observed at high doses (Guillem and Peoples, 2010; Wouda et al, 2011) . In addition, α-conotoxin MII should be used to determine the involvement of α3β2 and α6 nAChRs in the VTA in Varenicline reduces context-induced relapse F Lacroix et al context-induced relapse to alcohol-seeking. Finally, the anterior and posterior aspects of the VTA should be investigated separately, as the posterior but not anterior VTA has been implicated in the primary reinforcing properties of alcohol (Rodd-Henricks et al, 2000; Rodd et al, 2004) and a similar topographic gradient may exist for responding driven by alcohol cues.
Varenicline microinfused into the NAc reduced contextinduced relapse to alcohol-seeking, implicating ventral striatal nAChRs in this effect. Activation of cholinergic interneurons within the NAc elevates dopamine release (Cachope et al, 2012; Threlfell et al, 2012) , suggesting that nAChRs located on terminals of VTA projections to the NAc (Grady et al, 2002) regulate striatal dopamine levels. Thus, placement into an alcohol-associated context following extinction in a different context may increase acetylcholine in the NAc, causing an augmentation of dopamine through the actions of acetylcholine at presynaptic nAChRs located on the terminals of dopaminergic neurons. Varenicline may disrupt this signaling process by binding to these nAChRs, thereby attenuating relapse. Additional research is needed to test this hypothesis, and to parse out the potentially distinct contributions of the NAc core, shell and core/shell border subregions in the reduction of context-induced relapse to alcohol-seeking by varenicline. Notably, each rat in the present study showed this reduction regardless of where the injector tips were located within the ventral striatum, suggesting that subregion may not be a consideration when evaluating the impact of varenicline on context-induced relapse to alcohol-seeking.
Both systemic and intra-NAc varenicline reduced port entries during periods of the session that excluded the CS+ and CS − (Non-CS), suggesting that nAChRs may mediate alcohol-seeking signalled directly by the alcohol-associated context, in addition to alcohol-seeking triggered by presentations of the CS+ in the alcohol-associated context. Because systemic varenicline did not impact port entries during PDT and intra-NAc varenicline had no impact on latency to the first port entry in the relapse test, this explanation outweighs a varenicline-induced decrease in general locomotor behavior.
In conclusion, our data reveal a novel effect of varenicline on relapse triggered by an alcohol-associated context, and identify the NAc as a brain region that is central to this effect. These findings extend reports that varenicline reduced alcohol intake in humans (de Bejczy et al, 2015; Fucito et al, 2011; Litten et al, 2013; McKee et al, 2009) , decreased cue-induced relapse to alcohol-seeking in operant models (Funk et al, 2016; Wouda et al, 2011) , and diminished transient elevations in alcohol intake produced by periods of deprivation from alcohol (Sajja and Rahman, 2013) . The present data also suggest a new role for nAChRs in contextinduced relapse that extends to both pharmacological and non-drug reinforcers. They bolster the claim that carefully titrated doses of varenicline may help to maintain abstinence in individuals with alcohol use disorders (de Bejczy et al, 2015; Gowin et al, 2016; Litten et al, 2013; Soyka and Mutschler, 2015) , and open a door for further exploration into the precise neural processes that underlie the impact of varenicline on alcohol intake and relapse.
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